Drug Developers Need to More Fully Identify And Address Root Causes Of R&D Inefficiency, According To Tufts Center For The Study Of Drug Development

New Drug Approvals

Boston, MA–(Marketwire) – While patent expirations on many top selling medicines are spurring the research-based drug industry to embrace new development paradigms to replenish sparse R&D pipelines, drug developers need to more fully identify and address root causes of R&D inefficiency, according to the Tufts Center for the Study of Drug Development.

read all at


View original post

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s